Abstract
Summary
A new sulfonamide preparation has been presented which, on the basis of its high solubility in buffer solution, would be expected to greatly diminish the danger of sulfonamide crystallization in the kidney, with or without the concomitant administration of alkali. Neither crystallization nor the signs of renal irritation in the absence of crystallization were observed (except in the patient to whom enormous doses were administered). The antibacterial activity in vivo and in vitro and the low toxicity in the experimental animal combined to recommend an investigation of the clinical pharmacology of this compound. The blood and urine levels attained were found to be satisfactory and it was found possible to achieve and maintain these levels with an 8-hour dosage schedule. The entry of this drug into the spinal fluid of the normal individual is low, but in the presence of meningeal inflammation it was markedly increased in the one patient studied. The toxicity of the compound is low.
Get full access to this article
View all access options for this article.